BPC 157 Defends Against Cancer and Neurodegeneration by Mastering Angiogenesis and Nitric Oxide
Researchers rebut claims that BPC 157 promotes tumor growth or neurodegeneration, citing evidence it modulates—not dysregulates—angiogenesis and NO.
Summary
This commentary from University of Zagreb researchers directly rebuts a 2025 review suggesting BPC 157 could promote tumorigenesis and neurodegenerative disease via angiogenesis and nitric oxide over-stimulation. The authors argue BPC 157—a stable gastric pentadecapeptide—does not fit the profile of a harmful angiogenic agent. Instead, evidence shows it opposes corneal neovascularization, inhibits VEGF signaling, reduces lung metastases in mice, counteracts tumor cachexia, and modulates the NO system bidirectionally while always suppressing free radical formation. Animal models of Parkinson's and Alzheimer's disease show BPC 157 counteracts, rather than worsens, neurodegeneration. The authors frame BPC 157 as a cytoprotective agent that targets pathological angiogenesis and NO cytotoxicity while preserving their essential healing functions.
Detailed Summary
**Why This Matters:** BPC 157 is a synthetic pentadecapeptide derived from human gastric juice, studied extensively in preclinical models for wound healing, organ protection, and neuroprotection. A 2025 literature review by Józwiak et al. raised concerns that BPC 157's pro-angiogenic and NO-stimulatory properties could theoretically promote cancer and neurodegenerative conditions. This rebuttal from the leading BPC 157 research group at the University of Zagreb directly challenges those conclusions.
**What Was Argued and Reviewed:** The authors systematically address three key allegations: (1) that BPC 157 promotes harmful angiogenesis leading to tumorigenesis; (2) that it stimulates NO and eNOS in ways that generate damaging free radicals; and (3) that these mechanisms could worsen neurodegeneration. Drawing on decades of preclinical research, they invoke Folkman's corneal neovascularization model as a benchmark—arguing that genuine pro-tumorigenic angiogenic agents induce corneal neovascularization, whereas BPC 157 does the opposite, actively preventing it and maintaining corneal transparency.
**Key Results Cited:** BPC 157 (2 ng/mL–2 µg/mL) administered as eye drops healed corneal ulcers and suppressed neovascularization in all treated rats. In human melanoma cell lines, it inhibited VEGF effects in vitro. In mice, it substantially reduced melanoma B-16 lung metastases. In C26 colon adenocarcinoma models, it prolonged survival, corrected muscle wasting, and reduced IL-6 and TNF-alpha levels. Regarding NO, BPC 157 demonstrated a context-dependent bidirectional effect—counteracting both NOS inhibition (L-NAME-induced hypertension) and NOS over-activation (L-arginine-induced hypotension)—while consistently reducing lipid peroxidation markers (MDA via TBARS assay) across more than 80 experimental targets. In Parkinson's and Alzheimer's disease animal models (MPTP, reserpine, haloperidol, stroke), BPC 157 counteracted tremor, akinesia, catalepsy, brain lesions, and cognitive dysfunction.
**Implications:** The authors frame BPC 157 as operating through cytoprotection principles (Robert's and Szabo's model), selectively suppressing pathological angiogenesis and NO cytotoxicity while preserving their tissue-protective roles. Signaling pathways implicated include VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS. This positions BPC 157 as a modulatory, not dysregulatory, agent with potential across oncology, neurology, and wound healing.
**Caveats:** This is a commentary/rebuttal, not a primary study. The evidence cited relies predominantly on preclinical rodent models, and no human clinical trial data are presented. The claimed unpublished melanoma metastasis data require independent verification before conclusions can be drawn.
Key Findings
- BPC 157 suppressed corneal neovascularization in all treated rats, consistent with Folkman's anti-tumor angiogenesis model.
- BPC 157 inhibited VEGF signaling in human melanoma cells and reduced lung metastases in mice.
- NO modulation by BPC 157 is bidirectional and always accompanied by reduced lipid peroxidation (lower MDA levels).
- BPC 157 counteracted Parkinson's- and Alzheimer's-like symptoms across multiple validated rodent models.
- In C26 colon cancer mice, BPC 157 reduced IL-6/TNF-alpha, corrected muscle wasting, and extended survival.
Methodology
This is a published commentary rebutting a prior literature review. The authors synthesize findings from multiple preclinical studies using rodent models (rats and mice), in vitro human cell lines, and pharmacological NO-system probes (L-NAME, L-arginine, and their combination) to argue against alleged BPC 157 safety concerns.
Study Limitations
All supporting evidence is preclinical (rodent and cell culture); no randomized human clinical trial data are presented. The commentary format means claims are not independently peer-reviewed as primary research. One key dataset (melanoma metastasis reduction) is described as unpublished, limiting verification.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.